Soares Holly D, Chen Yu, Sabbagh Marwin, Roher Alex, Schrijvers Elisabeth, Breteler Monique
Pfizer Global Research and Development, Groton, Connecticut, USA.
Ann N Y Acad Sci. 2009 Oct;1180:56-67. doi: 10.1111/j.1749-6632.2009.05066.x.
Alzheimer's disease (AD) is a debilitating neurodegenerative disorder with incidence expected to increase four-fold over the next decade. Extensive research efforts are focused upon identifying new treatments, and early diagnosis is considered key to successful intervention. Although imaging and cerebrospinal fluid biomarkers have shown promise in identifying patients in very early stages of the disease, more noninvasive cost-effective tools have remained elusive. Recent studies have reported that an 18-analyte multiplexed plasma panel can differentiate AD from controls suggesting plasma-based screening tools for early AD diagnosis exists. The current study tested the reproducibility of a subset of the original 18-analyte panel using a bead-based multiplex technology. Preliminary results suggest diagnostic accuracy using the subset was 61%. Multivariate analysis of an 89-analyte multivariate panel yielded a diagnostic accuracy of 70% suggesting a plasma-based AD signature that may be a useful screening tool.
阿尔茨海默病（AD）是一种使人衰弱的神经退行性疾病，预计在未来十年发病率将增加四倍。大量研究工作集中在寻找新的治疗方法上，早期诊断被认为是成功干预的关键。尽管成像和脑脊液生物标志物在识别疾病极早期患者方面已显示出前景，但更多非侵入性且性价比高的工具仍难以找到。最近的研究报告称，一个包含18种分析物的多重血浆检测板能够区分AD患者和对照者，这表明存在基于血浆的早期AD诊断筛查工具。当前研究使用基于微珠的多重技术测试了原始18种分析物检测板中一个子集的可重复性。初步结果表明，使用该子集的诊断准确率为61%。对一个包含89种分析物的多变量检测板进行多变量分析，得出的诊断准确率为70%，这表明基于血浆的AD特征可能是一种有用的筛查工具。
